Background: Genome-wide association studies have recently shown that the rs12979860 polymorphism in IL28B is associated with the response to chronic hepatitis C treatment. The aim of this study was to investigate whether rs12979860 could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in the Chinese Han population. Methods: The rs12979860 genotype was detected in 259 individuals infected with HCV by DNA sequencing. Among them, 120 patients were administered complete pegylated interferon-α and ribavirin combination therapy and 92 patients were followed for 24 weeks after the cessation of treatment and were divided into different groups according to outcomes of treatment. Conclusions: This study demonstrated for the first time that the rs12979860 variation in IL28B could be a predictor of ETR and SVR in Chinese Han patients infected with HCV. The high frequency of the rs12979860 genotype CC might explain why the SVR rate is higher than that of the average global population.
HCV is classified in the family Flaviviridae and in the genus hepacivirus, with six major genotypes and multiple serotypes [1, 2] . Approximately 2.2% of the global population is infected with HCV, and 70-80% of exposed individuals suffer from a chronic infection [3, 4] . HCV infection is a leading cause of liver cirrhosis and hepatocellular carcinoma, and is therefore a major and growing global health problem [3, 4] . In China, a seroprevalence rate of 0.58% has been reported in a recent study [5] , which is lower than the global rate; however, HCV infection remains a major public health problem because of the large population base in China.
The currently available treatment for suitable patients with HCV infection is combination therapy consisting of pegylated interferon-α (PEG-IFN-α) and ribavirin (RBV). Globally, 54-63% of patients achieve sustained viral response (SVR) under combination therapy; however, the SVR rate is only 40-50% in patients infected with HCV genotype 1 [6] [7] [8] . The molecular mechanisms underlying failure of combination therapy are not well understood, but evidence indicates that both viral and host factors, such as HCV genotype, viral load, genetics, race, gender, age, body mass index and coexistent liver disease, could influence response rates [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] .
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Introduction
Host genetic factors might influence the ability to clear HCV following infection. Previous studies have investigated many genetic factors, such as the genetic polymorphisms of human leukocyte antigens and the interleukin-10 promoter, but the discoveries were variable and inconclusive [11, 12, [19] [20] [21] [22] . Recently, genome-wide association studies have confirmed that the rs12979860 variation, a polymorphism on chromosome 19, is associated with the response to anti-HCV treatment, both among patients of European ancestry and African-Americans [18] . The rs12979860 variation is located 3 kb upstream of the IL28B gene, which encodes one type III interferon (IFN) -IFN-λ3. IL28A and IL29 (also called IFN-λ2 and IFN-λ1, respectively) are the other two type III interferons, and are clustered on human chromosome 19q13 with IL28B [23] .
Some data have shown that the SVR rates in Asian patients are higher than non-Asian patients [15, 24] , and recent studies have suggested that the genetic variation in IL28B might be linked to the higher SVR rate in Asians [13, 18] . Thomas et al. [25] genotyped the rs12979860 variant in HCV cohorts comprising individuals who had spontaneously cleared the virus or who had persistent infection, and showed that patients with the CC genotype were associated with natural clearance of HCV. Furthermore, they genotyped 2,371 individuals from 51 populations worldwide and have shown that the rs12979860 C allele frequency in East Asia and Oceania is highest [25] . According to the Human Haplotype Map Project (HapMap), the data for Chinese Han showed that the frequency of rs12979860 genotype CC in the healthy population was also high (86.7%) [26] . In this study, we examined the prevalence rates of different rs12979860 genotypes (CC, CT and TT) in Chinese Han patients with HCV infection, and investigated the potential effects of the rs12979860 polymorphism in IL28B on outcomes of anti-HCV treatment. . Informed consent for a genetic test was obtained from each participant before inclusion in the study, and the study was approved by the hospital's ethics committee. The diagnosis of HCV infection was based on HCV antibody and HCV RNA detected in serum. Among these individuals, 120 patients infected with HCV genotype 1 or N-1 were administered 48 or 24 weeks of combination therapy, respectively, consisting of PEG-IFN-α and RBV, with medication doses according to treatment guidelines [27] . Of the 120 patients, 92 completed follow-up for 24 weeks after the cessation of treatment, and the remaining 28 are currently being monitored with follow-up examinations. None of these 120 patients were coinfected with HIV or any other hepatitis virus, nor were these cases complicated with decompensated liver disease or a serum creatinine level >1.5× the upper limit of normal. Furthermore, these individuals did not suffer from poorly controlled psychiatric disease, or alcohol or drug dependence. Among these treated patients, 16 received liver biopsy prior to treatment. Four patients had stage (S) 4 liver fibrosis, whereas the others were S1-S2. Undetectable serum HCV RNA at the end of either a 24-or 48-week course of therapy was referred to as an end-of-treatment response (ETR). The SVR was defined as absence of HCV RNA from serum by a sensitive PCR assay 24 weeks after discontinuation of therapy. The Cobas TaqMan HCV Test (Roche Molecular Diagnostics, Branchburg, NJ, USA), with a sensitivity of 15 IU/ml, was used for SVR and ETR classification. Those patients in which HCV RNA reappeared in serum after therapy were defined as relapsed responders (RR). Patients who failed to clear HCV RNA from serum after 24 or 48 weeks of therapy were defined as non-responders (NR). Patients with relapsed response or non-response were defined as having non-sustained virological response (N-SVR).
Methods
Patients
Genomic DNA extraction
Whole blood was taken from patients and genomic DNA was extracted using the Qiagen DNA Extraction Kit (Hilden, Germany) according to the manufacturer's instructions. The concentration of genomic DNA in each sample was determined by an ultraviolet spectrophotometer (Eppendorf, Hamburg, Germany) and samples were stored at -80°C until genetic polymorphism analyses were performed.
Genotyping of gene polymorphism
The rs12979860 genotype in IL28B was determined by DNA sequencing. First, PCR was performed to amplify the DNA fragment encompassing rs12979860 using the primers IL28F (5′-TCGCCAGGGCCCCTAACCTC-3′) and IL28R (5′-CCCAGCAGGCGCCTCTCCTA-3′). Amplification was performed using GoTaq DNA polymerase (Promega, Madison, WI, USA) in 50 µl reaction mixtures. Samples were cycled under the following conditions: 95°C for 2 min, then 40 cycles of 95°C for 30 s, 56°C for 45 s and 72°C for 1 min, followed by 72°C for 10 min to generate 297 base pair amplicons. PCR products were sequenced using the IL28F and IL28R sequencing primers using BigDye ® Terminator chemistry on an ABI 3730 Sequencer (Applied Biosystems, Foster City, CA, USA). Samples were genotyped according to the sequencing results.
HCV RNA quantification and genotyping HCV RNA was quantified using the Cobas TaqMan HCV Test (Roche Molecular Diagnostics). The HCV genotypes were determined by a commercial HCV genotyping Chip Kit (Realchip Biotechnology Co. Ltd, Shanghai, China) according to the manufacturer's instructions.
Statistical analyses
The Hardy-Weinberg equilibrium was tested by comparing the expected and observed genotype frequencies using the χ 2 test [28] . Fisher's exact tests were used to analyse the percentages of ETR and SVR by genotypes of rs12979860. Factors including sex (female versus male), age (<40 versus ≥40 years), HCV genotype (N-1 versus 1), baseline viral load (<600,000 versus ≥600,000 IU/ml) and rs12979860 genotype (CC versus N-CC) were analysed using multivariate analyses to explore the relationships between factors and outcomes of treatment. All analyses were carried out using SAS version 8.0 (SAS Institute, Inc., Cary, NC, USA). In all tests, a value of P<0.05 was considered statistically significant.
Results
Demographic and clinical features
Variations of rs12979860 were detected in 259 HCVinfected individuals by DNA sequencing ( Figure 1A) . In this study, the rs12979860 genotyping was within the Hardy-Weinberg equilibrium (P>0.05). The rs12979860 genotype CC (87.64%, 227/259) was the most common genotype and only one (0.39%, 1/259) individual had genotype TT. HCV 1b was the major (75.38%, 91/120) genotype in the 120 patients who were administered complete combination therapy (Figure 1B) . The characteristics of the 120 patients who were administered complete combination therapy and the 92 patients who were followed for 24 weeks after the cessation of treatment are shown in Tables 1 and 2, respectively. Among these individuals, 89 achieved ETR and 31 were NRs. Of the 92 patients who were followed for 24 weeks after the cessation of treatment, 58 achieved SVR and 34 individuals had N-SVR. The ETR and SVR rates were 74.17% (89/120) and 63.04% (58/92), respectively.
Rs12979860 genotypes and the antiviral response
Fisher's exact tests were used to assess antiviral response according to rs12979860 genotypes. Among the 120 patients who were administered complete combination therapy, 107 had rs12979860 genotype CC and 13 had genotype N-CC. Patients with rs12979860 genotype CC had a significantly higher proportion of ETR than patients with genotype N-CC (78.50% versus 38.46%; P=0.0044; Figure 2A ) and the rs12979860 genotype CC was a useful predictor of ETR (positive predictive value 78.50%, negative predictive value 61.54%, sensitivity 94.38%, specificity 25.81% and accuracy 76.67%). Among the 92 patients who were followed for 24 weeks after the cessation of treatment, 82 had rs12979860 genotype CC and 10 had genotype N-CC.
The patients with genotype CC had a much higher proportion of SVR than patients with genotype N-CC (68.29% versus 20%; P=0.0046; Figure 2B ) and the rs12979860 genotype CC was a useful predictor of SVR (positive predictive value 68.29%, negative predictive value 80.00%, sensitivity 96.55%, specificity 23.53% and accuracy 69.57%).
Factors associated with outcomes of treatment: multivariate analysis
We next tested whether sex (female versus male), age (<40 versus ≥40 years), HCV genotype (N-1 versus 1), baseline viral load (<600,000 versus ≥600,000 IU/ml) and rs12979860 genotypes (CC versus N-CC) were associated with ETR or SVR ( 
Discussion
Although the recommended treatment for chronic HCV infection involves combination therapy of PEG-IFN-α (PEG-IFN-α2a or PEG-IFN-α2b) and RBV, it is wellknown that many patients will not be cured by this treatment [6, 7] . To reduce the substantial cost and to avoid the side effects of combination therapy, it would be useful to identify predictors of response of an individual and to discover new antiviral drugs to treat the non-response patients. It has been reported that viral and host factors might influence the ability to clear HCV following infection [9] [10] [11] [12] [13] [14] [15] [16] . In this study, the rate of SVR (63.04%) in the Chinese Han population was higher than that of the global population; however, the reasons for this observation might be difficult to explain. For this reason, we analysed the relationship between the outcomes of anti-HCV treatment and viral or host factors, such as HCV genotype, baseline viral load, sex, age and rs12979860 genotypes. 
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Figure 2. Frequency of ETR and SVR with respect to rs12979860 genotypes
Fisher's exact tests were used to assess (A) end-of-treatment response (ETR) and (B) sustained virological response (SVR) according to rs12979860 genotypes in the 120 patients administered complete combination therapy and in the 92 patients who were followed for 24 weeks after cessation of complete combination therapy. NR, non-responder; N-SVR, non-sustained virological response. Recently, the rs12979860 genotype CC of IL28B was found to be significantly associated with a positive response to PEG-IFN-α and RBV in patients with chronic genotype 1 HCV infection among Hispanics, individuals of European ancestry and AfricanAmericans [18] ; however, the effects of the rs12979860 variation in the Chinese Han population remain unknown. In this study, we found that the rs12979860 genotype CC was significantly more common (87.64%) than the other genotypes. The high prevalence of this genotype might be related to the high response ratio to anti-HCV treatment in the Chinese Han population. To verify this hypothesis, we analysed the percentages of ETR and SVR in different genotypes of rs12979860 and found that patients with rs12979860 genotype CC had higher rates of ETR and SVR than patients with genotype N-CC. Considering the influence of sex, age, HCV genotype and baseline viral load, the multivariate analyses showed that rs12979860 genotype CC was strongly associated with ETR and SVR. These data suggest that the high frequency of the genotype CC in the Chinese Han population could be the reason that Chinese HCV patients have higher SVR rates in response to combination therapy than other ethnic groups.
The specific mechanisms responsible for the relationship between the rs12979860 variation and the outcomes of anti-HCV treatment remain largely unknown. This genetic variation is located 3 kb upstream of IL28B on chromosome 19q13, which encodes for IL28A, IL28B and IL29 (IFN-λ2, IFN-λ3 and IFN-λ1, respectively) [23] . IFN-λs, which have signalling mechanisms that are similar to type I IFN, but through a distinct receptor complex, can inhibit HCV replication in hepatoma cells containing an HCV replicon [29] [30] [31] . A recent study showed that the rs12979860 polymorphism was likely to be associated with natural clearance [25] . As such, it seems likely that the rs12979860 variation could be involved in the innate immune response to HCV. Some other variations in IL28B, such as rs8099917, rs12980275, rs8105790, rs11881222, rs8103142, rs28416813, rs4803219 and rs7248668, have been reported to be associated with the outcomes of anti-HCV treatment [13, 32, 33] . Considering that the rs12979860 variation was strongly associated with the different SVR rates in distinct ethnic groups [18] , we chose this single nucleotide polymorphism for our study described here. The rs12979860 is located upstream of IL28B and it is plausible that the variation is associated with the regulation of IL-28B transcription. However, Ge et al. [18] have carried out a study using the SNPExpress database and found no correlation with expression levels of IL28B in peripheral blood mononuclear cells from 80 HCV-uninfected individuals. Another study also showed no link between the rs12979860 variation and IL28B expression in the liver [34] . Thus, it needs further investigation to find out why the rs12979860 variation is strongly associated with the outcomes of anti-HCV treatment.
Severe side effects have been observed in HCV patients treated with IFN-α, such as influenza-like symptoms, fatigue, alopecia, suppression of bone marrow, emotional liability and worsening or unmasking of autoimmune disorders [35] . However, patients treated with IFN-λs might experience fewer adverse side effects because the receptors for this family of IFN are primarily expressed on epithelial cells and are notably absent on most haematopoietic cells [36, 37] . Recent clinical studies have reported that IFN-λ1 (PEG-rIL-29) had an antiviral effect in HCV patients without producing haematological toxicity [38] . As such, IFN-λs could be an alternative option for the treatment of HCV [39] and it might be a new direction for further research in improving the effect of anti-HCV treatment, especially for patients with the rs12979860 genotype N-CC who are resistant to IFN-α. Further research might be necessary to explain why rs12979860 genotype CC is strongly related to the high rates of ETR and SVR.
Other viral and host factors, including HCV genotype N-1, baseline viral load of <600,000 IU/ml, female gender and age <40 years, were reported to be associated with a high response to anti-HCV treatment [8, 16, 40] . In this study, two factors independently and significantly increased the odds of achieving ETR and SVR in the multivariate analyses: the HCV genotype N-1 and the rs12979860 genotype CC. The rs12979860 variation in IL28B was associated with a substantial difference in rates of achieving ETR and SVR.
In conclusion, the rs12979860 genotype CC in IL28B is associated with positive outcomes of anti-HCV treatment and genotypes could be used as a predictive marker for anti-HCV treatment response in the Chinese Han population. The high frequency of the rs12979860 genotype CC could be responsible for the higher SVR in the Chinese Han population compared with other ethnic groups. However, the mechanisms underlying the influences of rs12979860 on the outcome of anti-HCV combination therapy require further investigation.
